Several clinical trials are currently underway or in planning stages to evaluate the safety and efficacy of CRISPR-based therapies in cancer. Early results have been promising, particularly in blood cancers like leukemia and lymphoma, where CRISPR-engineered T-cells have shown the ability to target and kill cancer cells. However, more research is needed to determine the long-term effects and potential side effects of these treatments. As the technology advances, it is hoped that CRISPR will become a powerful tool in the fight against various types of cancer.
